Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bevacizumab + capecitabine
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Bevacizumab + capecitabine is a combination regimen used primarily for the treatment of metastatic colorectal cancer and other gastrointestinal malignancies. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and thereby restricting tumor blood supply. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), which interferes with DNA synthesis by inhibiting thymidylate synthase, leading to apoptosis in rapidly dividing cells. This combination aims to both directly kill tumor cells and disrupt their blood supply, improving outcomes in advanced cancers[1][3][5][6][8].
- Brand names
- XelodaAvastin
- Other names
- CAPE+BEVA RegimenCapecitabine-BevacizumabGIAVCAPB
02
Targets
VEGFA (Vascular endothelial growth factor A)TS (Thymidylate synthase)
Beyond the preview
Go deeper on Bevacizumab + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bevacizumab + capecitabine.